The latest financial statement is for the quarter ending 2025-09-30.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Total revenues | 108,273 | - |
| Cost of product sales | 0 | - |
| Cost of manufacturing services | 25,894 | - |
| Research and development | 113,198 | - |
| Selling, general and administrative | 29,925 | - |
| Other segment income (loss), net | -279 | - |
| Net loss | 16,822 | -77,287 |
| Depreciation and amortization expense | 1,789 | 3,678 |
| Amortization of premiums and discounts on marketable securities | 511 | 493 |
| Stock-based compensation | 3,549 | 8,076 |
| Non-cash royalty revenue | 3,333 | - |
| Non-cash interest expense recognized | 3,329 | 587 |
| Non-cash lease expense | 405 | 799 |
| Other adjustments | 0 | 0 |
| Accounts receivable | 56,698 | 8,223 |
| Inventory | -525 | 9,275 |
| Prepaid expenses and other current assets | 1,062 | -4,862 |
| Other non current assets | -5 | -159 |
| Accounts payable | 1,309 | -388 |
| Accrued expenses and other current liabilities | 1,738 | -7,651 |
| Lease liabilities | -238 | -214 |
| Deferred revenue | 2,525 | -8,205 |
| Other non current liabilities | -340 | -300 |
| Net cash used in operating activities | -30,186 | -93,875 |
| Purchases of marketable securities | 66,062 | 53,428 |
| Proceeds from sale and maturities of marketable securities | 46,117 | 26,936 |
| Purchases of property, equipment and software | 426 | 1,244 |
| Proceeds from sales of equipment | 0 | 0 |
| Net cash (used in) provided by investing activities | -20,371 | -27,736 |
| Proceeds from stock option exercises and espp purchases | 0 | 66 |
| Taxes paid related to net share settlement of equity awards | 0 | 282 |
| Net proceeds from sale of future royalties | 0 | 69,673 |
| Net cash provided by financing activities | 0 | 69,457 |
| Net change in cash and cash equivalents | -50,557 | -52,154 |
| Cash and cash equivalents at beginning of period | 182,840 | - |
| Cash and cash equivalents at end of period | 80,129 | - |
MACROGENICS INC (MGNX)
MACROGENICS INC (MGNX)